AI Readiness Index · South Korea · Q2 2026
Samsung Biologics
Order 200 of 1,000 in the published Q2 2026 Index, South Korea, Manufacturing. The order is the position in the published list, not a measure of quality. Public-evidence score 62.0 of 100, adjusted 62.0, tier Momentum, evidence grade A.
What the public record shows
| Measure | Value |
|---|---|
| Order in the published 1,000 | 200 |
| Public-evidence score | 62.0 of 100 |
| Adjusted score | 62.0 of 100 |
| Tier | Momentum |
| Evidence grade | A |
| Evidence recency | fresh |
| Market | South Korea |
| Sector | Manufacturing |
| Entity type | mnc subsidiary |
| Official evidence | 4 |
| Third-party evidence | 1 |
| Job evidence | 0 |
| Directory evidence | 1 |
| Domain | samsungbiologics.com |
What this page does not claim
This is a reading of public evidence, not an audit and not a finding about how well this organisation uses AI. It is built from public sources only. It is not an endorsement of this organisation, and being listed is not a relationship with AIR APAC. Where AIR APAC has a recorded relationship with an organisation, it is disclosed on the About page.